A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer

BACKGROUND: Everolimus significantly improves progression-free survival (PFS) and has been approved to use in aromatase inhibitor pretreated patients with hormone receptor positive advanced breast cancer. Metformin has been shown to inhibit mTOR pathway, with more favorable safety profile, leading t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yannan, Gong, Chengcheng, Wang, Zhonghua, Zhang, Jian, Wang, Leiping, Zhang, Sheng, Cao, Jun, Tao, Zhonghua, Li, Ting, Wang, Biyun, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663590/
https://www.ncbi.nlm.nih.gov/pubmed/29137418
http://dx.doi.org/10.18632/oncotarget.20478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663590/
https://www.ncbi.nlm.nih.gov/pubmed/29137418
http://dx.doi.org/10.18632/oncotarget.20478

Ejemplares similares